Kobe University

Osaka University

Morishita Jintan Co., Ltd.

Toshiro Shirakawa

Takane Katayama

Masanori Asada

Yoshiko Hashii

Masaaki Nakatsuji

Yasunobu Kano

Keiichi Ozono

Koichi Kitagawa

Hak Hotta

Michiko Taniguchi

Asako Okamoto

Sakura Yamamoto

Jun Wada

Tetsuo Takata

Kosuke Shimamoto

Masato Kawabata

Naoto Kunimura

Provided is a novel cancer gene therapeutic means. More specifically, provided is a nucleic acid having a structure in which (A) a nucleic acid encoding a protein having a CD44 extracellular function, (B) a nucleic acid encoding a protein having a Notch core region function, and (C) a nucleic acid encoding a protein having an HIF-3α4 function are linked in the order of (A)-(B)-(C).

Cancer gene therapy drug

It is an object to provide a combination therapy effective in cancer immunotherapy. The object is achieved by providing an anti-tumor agent, including a transformedcontaining DNA encoding a WT1 protein and DNA encoding a GNB/LNB substrate-binding membrane protein derived from a, the transformedbeing designed to display the WT1 protein as an antigen on a surface of the transformed, the anti-tumor agent being for use in combination with an immunosuppression inhibitor. The transformedcan be used as an oral tumor vaccine.

Cancer therapy utilizing combination of oral tumor vaccine and immunosuppression inhibitor

A cancer vaccine that can be orally administered can be provided through the use of a transformedcapable of expressing and displaying a WT1 protein. The WT1 protein expressed and displayed by the transformedis a protein covering most of a WT1 protein unlike a WT1 peptide vaccine restricted to a certain HLA. A cancer vaccine using the transformedas an active ingredient is applicable to patients of various HLA types.

Oral cancer vaccine

Provided is a gene for expressing an immunogenic polypeptide on the cell surface of a, and the gene includes a gene encoding the immunogenic polypeptide, the immunogenic polypeptide includes a predetermined base domain and at least one antigenic peptide, and the at least one antigenic peptide is linked on any of the N-terminal side and the C-terminal side of the base domain. The gene for expressing an immunogenic polypeptide on a cell surface of aof the present invention can further include a gene encoding a-derived GNB/LNB substrate-binding membrane protein.

Immunogenic polypeptide surface layer-expressing bifidobacterium

The present invention provides an oral vaccine against a bacterial infectious disease (e.g., typhoid fever, cholera, or dysentery). The oral vaccine of the present invention is a capsule formulation in which a transformed microorganism that expresses a flagellin antigen protein or that secretes a flagellin antigen protein out of the cell of the microorganism is encapsulated with an acid-resistant membrane. Examples of the microorganism include intestinal bacteria belonging to the genus, the genus, the genus, and the like. The form of the capsule formulation may be any one of a seamless capsule formulation, a soft capsule formulation, and a hard capsule formulation.

Oral vaccine

According to the present invention, there is provided a means of expressing and displaying a protein on the cell surface of a. In the gene for expressing a protein on the surface of aof the present invention, a gene coding for a-derived GNB/LNB substrate-binding membrane protein and a gene coding for the target protein or peptide are linked in this order from the 5' end side. Thus, atransformed by introducing the gene for expressing a protein on the surface of aof the present invention expresses the target protein or peptide on the surface thereof. When the target protein or peptide is an antigen protein or an antigen peptide, the transformedof the present invention is useful as an oral vaccine.

Gene expressing a bifidobacterium surface-presented fusion protein

Growing community of inventors

Hyogo, Japan

Toshiro Shirakawa